الفهرس 
L YMPHOMASOnly 14 pages are availabe for public view
 |  | from | 170 |  |  |
| | | from | 170 | | |
Abstract
Background: CD155-dependent signals not only influenced net tumor growth but also responsiveness to immune checkpoint therapies. Thus, blocking CD155 could be a rational strategy to improve current immunotherapeutic
Aim of the work: To assess CD155 in newly diagnosed Low grade B non Hodgkin Lymphomas as prognostic marker for remission
Patients and methods: -. CD 155 measured by Ellisa at the time of diagnosis of 50 patients newly diagnosed low grade B non Hodgjen Lymphomas and the remission status followed up prospectively at 3 and 6 months in hematology unit at Ain Shams University Hospital
Results: there were high statistically significant difference between CD155 level and cytogenetic risk and Eligibility for auto transplantation, there were statistically significant difference between CD155 level and B symptoms, there were high statistically significant difference between CD155 level and Radiology stage, BM infiltation, protocol after 3months, There were high statistically significant difference between CD155 level and Radiology stage, BM infiltration, CBC after 6 months There were high statistically significant difference between CD155 level and non Remission and CD155 had Sensitivity88.46% and Specificity75% as poor predictor of remission
Conclusion: The CD155 level is prognostic factors for remission in Low grade B non Hodgkin Lymphomas as high CD155 level is poor prognostic factors for response and remission with Sensitivity 88.46 %and Specificity75. %